Abstract
The pleural mesothelial cell is an essential cell in maintaining the normal homeostasis of the pleural space and it is also a central component of the pathophysiologic processes affecting the pleural space. In this review, we will review the defense mechanisms of the pleural mesothelium and changes in pleural physiology as a result of inflammatory, infectious, and malignant conditions with a focus on cytokine and chemokine networks. We will also review the processes involved in the pathogenesis of pleural fibrosis.
References
1.
Wang N: Mesothelial cells in situ; in Chretien J, Bignon J, Hirsch A (eds): The Pleura in Health and Disease. New York, Dekker, 1985, pp 23–42.
2.
Medzhitov R, Janeway CA Jr: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4–9.
3.
Ohtsuka A, Yamana S, Murakami T: Localization of membrane-associated sialomucin on the free surface of mesothelial cells of the pleura, pericardium, and peritoneum. Histochem Cell Biol 1997;107:441–447.
4.
Sassetti C, Van Zante A, Rosen SD: Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J Biol Chem 2000;275:9001–9010.
5.
Sharma RK, Mohammed KA, Nasreen N, Hardwick J, Van Horn RD, Ramirez-Icaza C, Antony VB: Defensive role of pleural mesothelial cell sialomucins in tumor metastasis. Chest 2003;124:682–687.
6.
Owens MW, Milligan SA, Grisham MB: Nitric oxide synthesis by rat pleural mesothelial cells: induction by growth factors and lipopolysaccharide. Exp Lung Res 1995;21:731–742.
7.
Owens MW, Grisham MB: Nitric oxide synthesis by rat pleural mesothelial cells: induction by cytokines and lipopolysaccharide. Am J Physiol 1993;265:L110–L116.
8.
Heine H, Ulmer AJ: Recognition of bacterial products by toll-like receptors. Chem Immunol Allergy 2005;86:99–119.
9.
Delves PJ, Roitt IM: The immune system: second of two parts. N Engl J Med 2000;343:108–117.
10.
Delves PJ, Roitt IM: The immune system: first of two parts. N Engl J Med 2000;343:37–49.
11.
Mohammed KA, Nasreen N, Ward MJ, Antony VB: Induction of acute pleural inflammation by Staphylococcus aureus: CD4+ T cells play a critical role in experimental empyema. J Infect Dis 2000;181:1693–1699.
12.
Antony VB: Immunological mechanisms in pleural disease. Eur Respir J 2003;21:539–544.
13.
Jonjic N, Peri G, Bernasconi S, Sciacca F, Colotta F, Pelicci P, Lanfrancone L, Mantovani A: Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 1992;176:1165–1174.
14.
Antony VB, Hott JW, Kunkel SL, Godbey SW, Burdick MD, Strieter RM: Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am J Respir Cell Mol Biol 1995;12:581–588.
15.
Janeway CR, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002;20:197–216.
16.
Tosi MF: Innate immune responses to infection. J Allergy Clin Immunol 2005;116:241–249.
17.
Schnare M, Rollinghoff M, Qureshi S: Toll-like receptors: sentinels of host defence against bacterial infection. Int Arch Allergy Immunol 2006;139:75–85.
18.
Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J: Human beta-defensins. Cell Mol Life Sci 2006;63:1294–1313.
19.
Niyonsaba F, Ogawa H, Nagaoka I: Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004;111:273–281.
20.
Ashitani J, Mukae H, Nakazato M, Taniguchi H, Ogawa K, Kohno S, Matsukura S: Elevated pleural fluid levels of defensins in patients with empyema. Chest 1998;113:788–794.
21.
Strieter RM, Koch AE, Antony VB, Fick RB Jr, Standiford TJ, Kunkel SL: The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994;123:183–197.
22.
Broaddus VC, Boylan AM, Hoeffel JM, Kim KJ, Sadick M, Chuntharapai A, Hebert CA: Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of endotoxin-induced pleurisy. J Immunol 1994;152:2960–2967.
23.
Antony VB, Sahn SA, Antony AC, Repine JE: Bacillus Calmette-Guerin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest 1985;76:1514–1521.
24.
Ellner JJ, Barnes PF, Wallis RS, Modlin RL: The immunology of tuberculous pleurisy. Semin Respir Infect 1988;3:335–342.
25.
Malech H: Phagocytic cells: egress from marrow and diapedesis; in Gallin JG, Goldstein IM, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates. New York, Raven, 1988, pp 297–308.
26.
Broaddus VC, Yang L, Scavo LM, Ernst JD, Boylan AM: Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 1996;98:2050–2059.
27.
Nasreen N, Hartman D, Mohammed K, Antony V: Talc induces pleural mesothelial cell expression of proinflammatory cytokines and intracellular adhesion molecule (ICAM-1). Am J Respir Crit Care Med 1998;158:971–978.
28.
Spitznagel J: Nonoxidative antimicrobial reactions of leukocytes. Contemp Top Immunobiol 1984;14:283–343.
29.
Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI: Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:1427–1435.
30.
Cox G, Gauldie J, Jordana M: Bronchial epithelial cell-derived cytokines (G-CSF and GM-CSF) promote the survival of peripheral blood neutrophils in vitro. Am J Respir Cell Mol Biol 1992;7:507–513.
31.
Nasreen N, Mohammed KA, Sanders KL, Hardwick J, Van Horn RD, Loghmani F, Lundin MC, Antony VB: Differential expression of C-phos, C-June, and apoptosis in pleural mesothelial cells exposed to Staph. aureus. Am J Respir Crit Care Med 2001;163: A772.
32.
Payne CM, Glasser L, Tischler ME, Wyckoff D, Cromey D, Fiederlein R, Bohnert O: Programmed cell death of the normal human neutrophil: an in vitro model of senescence. Microsc Res Tech 1994;28:327–344.
33.
Sahn SA: State of the art: the pleura. Am Rev Respir Dis 1988;138:184–234.
34.
Mantovani A, Garlanda C: Novel pathways for negative regulation of inflammatory cytokines centered on receptor expression. Dev Biol Stand 1999;97:97–104.
35.
Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, van Dommelen SL, Degli-Esposti MA, Hayakawa Y: Activation of NK cell cytotoxicity. Mol Immunol 2005;42:501–510.
36.
Loghmani F, Mohammed KA, Nasreen N, Van Horn RD, Hardwick JA, Sanders KL, Antony VB: Inflammatory cytokines mediate C-C (monocyte chemotactic protein 1) and C-X-C (interleukin 8) chemokine expression in human pleural fibroblasts. Inflammation 2002;26:73–82.
37.
Hott JW, Godbey SW, Antony VB: Mesothelial cell modulation of pleural repair: thrombin stimulated mesothelial cells release prostaglandin E2. Prostaglandins Leukot Essent Fatty Acids 1994;51:329–335.
38.
Rennard S, Jaurand M, Bignon J, Ferrans V, Crystal R: Connective tissue matrix of the pleura; in Chretien J, Bignon J, Hirsch A (eds): The Pleura in Health and Disease. New York, Dekker, 1985, pp 69–85.
39.
Antony VB: Pathogenesis of malignant pleural effusions and talc pleurodesis. Pneumologie 1999;53:493–498.
40.
Ponta H: The CD44 protein family. Int J Biochem Cell Biol 1998;30:299–305.
41.
Bourguignon LY, Lokeshwar VB, Chen X, Kerrick WG: Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J Immunol 1993;151:6634–6644.
42.
Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, Loghmani F, Antony VB: Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res 2002;13:71–78.
43.
Sriram PS, Mohammed KA, Nasreen N, Hardwick J, Van Horn R, Sanders K, Antony VB: Adherence of ovarian cancer cells induces pleural mesothelial cell (PMC) permeability. Oncol Res 2002;13:79–85.
44.
Nasreen N, Mohammed KA, Antony VB: Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006;107:2425–2435.
45.
Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10:5145–5150.
46.
Kinch MS, Moore MB, Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003;9:613–618.
47.
Easty DJ, Herlyn M, Bennett DC: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995;60:129–136.
48.
Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM, Suo Z: Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res 2005;25:2943–2950.
49.
Nasreen N, Mohammed KA, Lai Y, Antony VB: Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett 2007;258:215–222.
50.
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277–285.
51.
Nasreen N, Mohammed KA, Sanders K, Hardwick J, Van Horn RD, Sriram PS, Ramirez-Icaza C, Hage C, Antony VB: Pleural mesothelial cell (PMC) defense mechanisms against malignancy. Oncol Res 2003;14:155–161.
52.
Nasreen N, Mohammed KA, Brown S, Su Y, Sriram PS, Moudgil B, Loddenkemper R, Antony VB: Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J 2007;29:761–769.
53.
Becker PM, Alcasabas A, Yu AY, Semenza GL, Bunton TE: Oxygen-independent upregulation of vascular endothelial growth factor and vascular barrier dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. Am J Respir Cell Mol Biol 2000;22:272–279.
54.
Thickett DR, Armstrong L, Millar AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707–710.
55.
Ishimoto O, Saijo Y, Narumi K, Kimura Y, Ebina M, Matsubara N, Asou N, Nakai Y, Nukiwa T: High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 2002;63:70–75.
56.
Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE, Antony VB: Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001;281:L119–L125.
57.
Corada M, Liao F, Lindgren M, Lampugnani MG, Breviario F, Frank R, Muller WA, Hicklin DJ, Bohlen P, Dejana E: Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 2001;97:1679–1684.
58.
Blankesteijn WM, van Gijn ME, Essers-Janssen YP, Daemen MJ, Smits JF: Beta-catenin, an inducer of uncontrolled cell proliferation and migration in malignancies, is localized in the cytoplasm of vascular endothelium during neovascularization after myocardial infarction. Am J Pathol 2000;157:877–883.
59.
Dejana E: Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1996;98:1949–1953.
60.
Lee YC, Lane KB: The many faces of transforming growth factor-beta in pleural diseases. Curr Opin Pulm Med 2001;7:173–179.
61.
Antony VB, Sahn SA, Mossman B, Gail DB, Kalica A: Pleural cell biology in health and disease. Am Rev Respir Dis 1992;145:1236–1239.
62.
Harvey W, Amlot PL: Collagen production by human mesothelial cells in vitro. J Pathol 1993;19:445–452.
63.
Ma C, Tarnuzzer RW, Chegini N: Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-beta 1. Wound Repair Regen 1999;7:477–485.
64.
Idell S, Zweib C, Kumar A, Koenig KB, Johnson AR: Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 1992;7:414–426.
65.
Falk P, Ma C, Chegini N, Holmdahl L: Differential regulation of mesothelial cell fibrinolysis by transforming growth factor beta 1. Scand J Clin Lab Invest 2000;60:439–447.
66.
Sasse SA, Jadus MR, Kukes GD: Pleural fluid transforming growth factor-β1 correlates with pleural fibrosis in experimental empyema. Am J Respir Crit Care Med 2003;168:700–705.
67.
Maeda J, Ueki N, Ohkawa T, Iwahashi N, Nakano T, Hada T, Higashino K: Local production and localization of transforming growth factor-beta in tuberculous pleurisy. Clin Exp Immunol 1993;92:32–38.
68.
Jagirdar J, Lee TC, Reibman J, Gold LI, Aston C, Begin R, Rom WN: Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 1997;105(suppl 5):1197–1203.
69.
Light RW, Cheng DS, Lee YCG, Rogers J, Davidson J, Lane KB: A single intrapleural injection of transforming growth factor beta-2 produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med 2000;162:98–104.
70.
Lee YCG, Lane KB, Parker RE, Ayo DS, Rogers JT, Diters RW, Thompson PJ, Light RW: Transforming growth factor β2 (TGF-β2) produces effective pleurodesis in sheep with no systemic complications. Thorax 2000;55:1058–1062.
71.
Mutsaers SE, McAnulty RJ, Laurent GJ, Versnel MA, Whitaker D, Papadimitriou JM: Cytokine regulation of mesothelial cell proliferation in vitro. Eur J Cell Biol 1997;72:24–29.
72.
Bikfalvi A, Klein S, Pintucci G, Rifkin DB: Biologic roles of fibroblast growth factor-2. Endocr Rev 1997;18:26–45.
73.
Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I: A heparin-binding angiogenic protein – basic fibroblast growth factor – is stored within basement membrane. Am J Pathol 1988;130:393–400.
74.
Friesel RE, Maciag T: Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995;9:919–925.
75.
Abramov Y, Anteby SO, Fasouliotis SJ, Barak V: Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. Am J Obstet Gynecol 2001;184:354–355.
76.
Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A: Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 2001;18:1093–1098.
77.
Antony VB, Nasreen N, Mohammed KA, Sriram PS, Frank W, Schoenfeld N, Loddenkemper R: Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest 2004;126:1522–1528.
78.
Owens MW, Milligan SA: Growth factor modulation of rat pleural mesothelial cell mitogenesis and collagen synthesis. Effects of epidermal growth factor and platelet-derived factor. Inflammation 1994;18:77–87.
79.
Waters CM, Chang JY, Glucksberg MR, DePaola N, Grotberg JB: Mechanical forces alter growth factor release by pleural mesothelial cells. Am J Physiol 1997;272:L552–L557.
80.
Safi A, Sadmi M, Martinet N, Menard O, Vaillant P, Gallati H, Hosang M, Martinet Y: Presence of elevated levels of platelet-derived growth factor (PDGF) in lung adenocarcinoma pleural effusions. Chest 1992;102:204–207.
81.
Heldin P, Asplund T, Ytterberg D, Thelin S, Laurent TC: Characterization of the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-derived growth factor in human mesothelial cells. Biochem J 1992;283:165–170.
82.
Adamson IYR, Prieditis H, Young L: Lung mesothelial cell and fibroblast responses to pleural and alveolar macrophage supernatants and to lavage fluids from crocidolite-exposed rats. Am J Respir Cell Mol Biol 1997;16:650–656.
83.
Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, Deuel TF: Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol 1989;109:429–440.
84.
Idell S: Pleural fibrosis; in Light RW, Lee YCG (eds): Textbook of Pleural Diseases. London, Arnold, 2003, pp 96–108.
85.
Mutsaers SE, Prele CM, Brody AR, Idell S: Pathogenesis of pleural fibrosis. Respirology 2004;9:428–440.
86.
Idell S, Girard W, Koenig KB, McLarty J, Fair DS: Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991;144:187–194.
87.
McGee M, Rothberger H: Tissue factor in bronchoalveolar lavage fluids. Evidence for an alveolar macrophage source. Am Rev Respir Dis 1985;131:331–336.
88.
Idell S, Zwieb C, Boggaram J, Holiday D, Johnson AR, Raghu G: Mechanisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-β and TNF-α. Am J Physiol 1992;263:L487–L494.
89.
Bajaj MS, Pendurthi U, Koenig K, Pueblitz S, Idell S: Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells and lung fibroblasts. Eur Respir J 2000;15:1069–1078.
90.
Vassalli JD, Sappino AP, Berlin D: The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067–1072.
91.
Shetty S, Kumar A, Johnson AR, Idell S: Regulation of mesothelial cell mitogenesis by antisense oligonucleotides for the urokinase receptor. Antisense Res Dev 1995;5:307–314.
92.
Sitrin RG, Todd RF 3rd, Albrecht E, Gyetko MR: The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996;97:1942–1951.
93.
Shetty S, Idell S: A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. Am J Physiol 1998;274:L871–L872.
94.
Chapman HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714–724.
95.
Shetty S, Kumar A, Johnson AR, Pueblitz S, Holiday D, Raghu G, Idell S: Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am J Respir Cell Mol Biol 1996;15:78–87.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
